Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

@Swing schreef op 9 december 2018 12:57:

[...]

@Dehardewerker: constateringen blijven herhalen en de manier waarop soms lijkt op leedvermaak. In mijn inziens lijk je mee te gaan daarin waardoor de uitspraak daarover in mijn ogen niet gewaagd was. Mijn excuses daarvoor..
Maar ik hoop dat iedereen winst pakt, op naar de nieuwe beursweek..

quote:

Eric de Rus schreef op 8 december 2018 18:01:

[...]

Ik heb vroeger wel veel op papier gedaan. Optieconstructies uitgeprobeerd.

Let wel: op papier handelen wijkt wel erg af van "in 't echie". Op papier ga je toch makkelijker met emoties om.

De positie (op papier) in Pharming heb ik louter gedaan omdat ik hier post.

Daarnaast ben ik vaak actief op het TA-draadje van IEX. Komt omdat daar meer mensen zitten die met opties speculeren. In TA geloof ik zelf namelijk niet :)

quote:

't zal maar gebeuren schreef op 8 december 2018 19:04:

[...]
als elke post van jou ,die op de man speelt ,verwijderd wordt, of een ban oplevert krijgt henk het nog behoorlijk druk.
je kakelt steeds dat iemand op de man speelt en vervolgens doe je hetzelfde.

quote:

Eric de Rus schreef op 8 december 2018 20:52:

[...]

Ja joh, Ruconest zou ook werken bij zwangerschapsvergiftiging. Kan hoor. Verder las ik al reacties als zou Ruconest ook al onderzocht worden tegen kanker.

Het is geen Haarlemmer olie.

quote:

Bosso schreef op 9 december 2018 12:58:

[...]
O.K. jij gelijk, maar misschien wist hij bij de presentatie al iets meer over de rest van het jaar.

quote:

maliqun61 schreef op 9 december 2018 13:06:

Het duurt nog een tijdje, maar de tijd vliegt toch:

Solebury Trout Annual 1x1 Management Access Event
San Francisco, CA, United States, January 7 – January 10, 2019

troutaccess.com/investor.php/c/solebu...

Participating Companies oa

Pharming Group NV: RUCONEST (rhC1INH) marketed to treat acute Hereditary Angioedema (HAE) attacks with 100% response rate, no relapse, side effects, or plasma risk. Submitted sBLA to FDA for prophylaxis of HAE (recent CRL requesting additional trial). Cash flow positive. Recently announced positive results from a ph2 study of RUCONEST in Contract-induced Nephropathy for patients receiving elective coronary angiography with or without a percutaneous coronary intervention (PCI). Recently filed for approval to begin the first clinical study of RUCONEST in pre-eclampsia, and pursuing additional indications in cardiac protection. Development programs in Pompe and Fabry diseases, Haemophillia.

quote:

De Monitor schreef op 8 december 2018 10:20:

[...]

Zal gezellig worden als er eentje bij zit die het koersdoel iets naar beneden bij stelt.
Ook analisten worden afgerekend op hun prestaties qua koersdoelen.

quote:

patje2 schreef op 9 december 2018 14:26:

Worden juillie daar echt ni moe van altijd dat Kempen rapport alles ik hier schrijf iedereen moet rode sokken dragen morgen doen jullie dat dan ook wil is iets anders lezen hier

quote:

Techspec schreef op 9 december 2018 14:33:

De resultaten van een onafhankelijk vergelijkend onderzoek tussen Ruconest, Firazyr, Berinert en Cinryze is inmiddels ook te zien op de Hae website:

Favorable conclusion from study of acute HAE therapies = Ruconest!
(Ruconest werkt het effectiefst, is veilig en ook nog eens het goedkoopst in gebruik)

A new study examines and compares re-dosing rates inter alia for human C1 esterase inhibitor in recombinant form (Ruconest®) and plasma-derived forms (Berinert®, Cinryze®) to icatibant (Firazyr®) in seven individual patients at risk of HAE attacks. A total of 69 attacks were recorded. The study was led by Professor Dr Marcus Magerl of the Department of Dermatology and Allergy at the Charité Universitätsmedizin Berlin, Berlin, Germany. The main outcome of the study was that treatment with recombinant therapy Ruconest® and plasma-derived C1 treatments requires significantly less re-dosing than icatibant (Firazyr®) to resolve HAE attacks.

There were 69 initial attacks in total across all seven patients. In this real-world study, the patients were able to choose the treatment for their attack. Following initial intervention, some patients needed to treat their attacks with a second dose or subsequent treatments to try to resolve the attack. The choice of the subsequent re-treatments was also decided by the patient. The majority of the attacks were classified as mild (67%), with 27% moderate and 6% severe.

Patients treated their attack initially with either Berinert® (five attacks) or Cinryze® (17 attacks), both plasma-derived C1 esterase inhibitors (“pdC1INH”), or Firazyr® (25 attacks) (icatibant, a small molecule bradykinin inhibitor, “Icatibant”), or Ruconest® (20 attacks), a recombinant human C1 esterase inhibitor (“rhC1INH”).

In the study, Ruconest® showed 100% efficacy with first dose at appropriate clinical levels. In two cases, additional therapy was applied because of initial underdosing of the first treatment. Cinryze® and Berinert® also showed good results.

The main difference, however, was shown in those patients who selected Firazyr® as their first line therapy. These patients recorded re-dosing rates that were higher than controlled clinical studies have indicated before.

Of the 25 attacks treated with Firazyr® as a first line therapy, 11 (44%) failed on the first dose. In eight of those 11 failed therapy situations (72%), the patient took a second dose of Firazyr® to try to end the attack. In the other three cases, the patients took a C1 esterase inhibitor (two taking Berinert®, and one Ruconest®).

All of the patients who took a C1 esterase inhibitor reported the attack resolved, whereas in a further five of the eight Firazyr® treatments patients had to take a third dose of medication to try to resolve the attack. Where either Ruconest® (two) or Berinert® (one) were used as the third treatment of the attack, it was again resolved, whereas one out of two attacks re-treated with Firazyr® required a fourth dose of Firazyr® for the attack to be resolved.

Further data regarding reasons for drug selection and subjective observations on the performance of the drugs in each attack are being analysed and the full results of the study will be published by the investigators in due course.

Dr Bruno Giannetti, Chief Operations Officer of Pharming Group N.V., said:

“This was a well-run independent investigator-led comparative study under real world conditions, which gives a clear signal confirming reports from patients: Treatment with adequate doses of C1 esterase inhibitor is an excellent therapy to minimize and end an acute HAE attack. It also confirms that re-dosing with icatibant is often needed to successfully treat an attack. In fact, this study reports failure rates for treatment with icatibant of 44% for the first dose and 62% for the second dose, with one of the patients needing to take four doses to stop one attack.”
(Source: Pharming)

haei.org/favorable-conclusion-from-st...

quote:

Techspec schreef op 9 december 2018 13:15:

[...]

Hoe moet ik dit dan zien t.a.v. de aflossingen op je hypotheek?